ClinicalTrials.gg

Program

belimumab

Also written as “Belimumab”, “Belimumab 10 mg/kg” and “Belimumab 1 mg/kg”.

Its studies are mostly in Lupus Erythematosus, Systemic · Glomerulonephritis, Membranous · Arthritis, Rheumatoid · Connective Tissue Diseases · Scleroderma, Systemic, led by 2 companies.

Furthest: phase 4, since May 8, 201239 company-led studies, 6 open or runningNext primary completion: Jun 29, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline386 open or runningphase 4since May 8, 2012Oct 24, 2003Jun 29, 2027phase 4 · NCT06411249
Johnson & Johnson10 open or runningphase 1since Oct 29, 2020Oct 29, 2020none ahead

Also a collaborator on its studies: icon-plc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 25 studies since Oct 24, 2003.

  1. Jan 4, 2013Phase 2 study in Glomerulonephritis, MembranousGlaxoSmithKline · NCT01762852 · United States, Australia, Canada and more
  2. Jul 3, 2013Phase 1 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT01894360 · 81 enrolled · United States
  3. Apr 17, 2014Phase 3 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT02119156 · 80 enrolled · United States, China, Japan and more
  4. Dec 14, 2015Phase 2 study in Sjogren's SyndromeGlaxoSmithKline · NCT02631538 · 86 enrolled · Argentina, Canada, France and more
  5. Aug 23, 2016Phase 1 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT02880852 · 20 enrolled · China
  6. Nov 25, 2019Phase 2 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT04179032 · 25 enrolled · United States, Argentina, Germany and more
  7. Oct 29, 2020Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT04611971 · 13 enrolled · Belgium
  8. May 26, 2021Phase 4 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT04908865 · 67 enrolled · China
  9. May 19, 2023Phase 3 study in Scleroderma, SystemicGlaxoSmithKline · NCT05878717 · 300 planned · United States, Argentina, Australia and more
  10. Jun 14, 2023Phase 1 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT05917288 · 16 enrolled · China
  11. May 8, 2024Phase 4 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT06411249 · 302 enrolled · United States, Argentina, Brazil and more
  12. Aug 16, 2024Phase 3 study in Lung Diseases, InterstitialGlaxoSmithKline · NCT06572384 · 440 planned · United States, Argentina, Australia and more
  13. Aug 26, 2024Phase 1 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT06576271 · 143 enrolled · United States, Argentina, Brazil and more
  14. Nov 29, 2024Phase 3 study in Connective Tissue DiseasesGlaxoSmithKline · NCT06716606 · 514 planned · United States, Argentina, Australia and more

Ahead

  1. Jun 29, 2027Primary completion: phase 4 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT06411249
  2. Feb 1, 2028Primary completion: phase 1 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT06576271
  3. Aug 30, 2029Primary completion: phase 3 study in Lung Diseases, InterstitialGlaxoSmithKline · NCT06572384
  4. Aug 30, 2029Primary completion: phase 3 study in Scleroderma, SystemicGlaxoSmithKline · NCT05878717

TargetBeta

TNFSF13B →read by rule
“Tumor necrosis factor ligand superfamily member 13B inhibitor”ChEMBL 37, by rule

Other programs on TNFSF13B

ProgramCompanyFurthest phaseStudies
tibulizumabruleEli Lillyphase 25

Studies

All 39 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06716606Connective Tissue Diseases · United States, Argentina, Australia and more3RecruitingGlaxoSmithKlineSep 27, 2030514
NCT06576271Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more1Active, not recruitingGlaxoSmithKlineFeb 1, 2028143
NCT06572384Lung Diseases, Interstitial · United States, Argentina, Australia and more3RecruitingGlaxoSmithKlineAug 30, 2029440
NCT06411249Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more4Active, not recruitingGlaxoSmithKlineJun 29, 2027302
NCT05917288Lupus Erythematosus, Systemic · China1CompletedGlaxoSmithKlineOct 30, 202416
NCT05878717Scleroderma, Systemic · United States, Argentina, Australia and more3RecruitingGlaxoSmithKlineAug 30, 2029300
NCT04908865Lupus Erythematosus, Systemic · China4CompletedGlaxoSmithKlineMay 23, 202467
NCT04611971Healthy · Belgium1CompletedJohnson & JohnsonMay 6, 202113
NCT04179032Lupus Erythematosus, Systemic · United States, Argentina, Germany and more2Active, not recruitingGlaxoSmithKlineJan 16, 202325
NCT02880852Lupus Erythematosus, Systemic · China1CompletedGlaxoSmithKlineSep 8, 201720
NCT02631538Sjogren's Syndrome · Argentina, Canada, France and more2CompletedGlaxoSmithKlineJun 23, 202086
NCT02119156Lupus Erythematosus, Systemic · United States, China, Japan and more3CompletedGlaxoSmithKlineDec 14, 201880
NCT01894360Lupus Erythematosus, Systemic · United States1CompletedGlaxoSmithKlineMay 13, 201481
NCT01762852Glomerulonephritis, Membranous · United States, Australia, Canada and more2WithdrawnGlaxoSmithKlineJan 20140
NCT01705977Lupus Erythematosus, Systemic · United States, Argentina, Australia and more4CompletedGlaxoSmithKlineJul 30, 20184,019
NCT01663623Vasculitis · United States, Australia, Belgium and more3CompletedGlaxoSmithKlineFeb 6, 2017106
NCT01649765Lupus Erythematosus, Systemic · United States, Argentina, Canada and more2CompletedGlaxoSmithKlineJan 24, 201893
NCT01639339Lupus Nephritis · United States, Argentina, Belgium and more3CompletedGlaxoSmithKlineJul 25, 2019448
NCT01632241Lupus Erythematosus, Systemic · United States, Brazil, Colombia and more4CompletedGlaxoSmithKlineJun 18, 2018503
NCT01610492Glomerulonephritis, Membranous · United Kingdom2CompletedGlaxoSmithKlineSep 24, 201414
NCT01597622Lupus Erythematosus, Systemic · Japan, Korea, Republic of3CompletedGlaxoSmithKlineSep 13, 2018142
NCT01597492Lupus Erythematosus, Systemic · United States4CompletedGlaxoSmithKlineSep 1, 201579
NCT01583530Lupus Erythematosus, Systemic · United States1CompletedGlaxoSmithKlineSep 2011118
NCT01536379Infections · United Kingdom2CompletedGlaxoSmithKlineFeb 201630
NCT01484496Lupus Erythematosus, Systemic · United States, Argentina, Austria and more3CompletedGlaxoSmithKlineFeb 13, 2015839
NCT01480596Myasthaenia Gravis · United States, Canada, Germany and more2CompletedGlaxoSmithKlineAug 201540
NCT01440361Purpura2WithdrawnGlaxoSmithKlineApr 20150
NCT01345253Lupus Erythematosus, Systemic · China, Japan, South Korea3CompletedGlaxoSmithKlineSep 15, 2015709
NCT01381536Lupus Erythematosus, Systemic · Japan1CompletedGlaxoSmithKlineNov 27, 201012
NCT00732940Lupus Erythematosus, Systemic · United States, Mexico2TerminatedGlaxoSmithKlineOct 200956
NCT00724867Lupus Erythematosus, Systemic · United States3CompletedGlaxoSmithKlineMar 2015268
NCT00712933Lupus Erythematosus, Systemic · Argentina, Austria, Belgium and more3CompletedGlaxoSmithKlineDec 9, 2016738
NCT00657007Lupus Erythematosus, Systemic · United States1CompletedGlaxoSmithKlineMar 200370
NCT00583557Arthritis, Rheumatoid · United States, Poland2TerminatedGlaxoSmithKlineNov 2009155
NCT00583362Lupus Erythematosus, Systemic · United States, Canada2CompletedGlaxoSmithKlineFeb 23, 2016298
NCT00424476Lupus Erythematosus, Systemic · Argentina, Australia, Brazil and more3CompletedGlaxoSmithKlineMay 2009865
NCT00410384Lupus Erythematosus, Systemic · United States, Austria, Belgium and more3CompletedGlaxoSmithKlineSep 2009819
NCT00071812Arthritis, Rheumatoid · United States2CompletedGlaxoSmithKlineJan 2005283
NCT00071487Lupus Erythematosus, Systemic · United States, Canada2CompletedGlaxoSmithKlineAug 2005449

How it is read

Names in the registry

  • “Belimumab”, 16 entries
  • “Belimumab 10 mg/kg”, 7 entries
  • “belimumab”, 7 entries
  • “Belimumab 1 mg/kg”, 5 entries
  • “Belimumab 10 mg/kg plus standard therapy”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.